AbCellera Biologics Inc. Files 8-K
Ticker: ABCL · Form: 8-K · Filed: Sep 10, 2025 · CIK: 1703057
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
TL;DR
AbCellera filed an 8-K on Sept 10, 2025. Standard corporate update.
AI Summary
AbCellera Biologics Inc. filed an 8-K on September 10, 2025, reporting other events and financial statements. The company, incorporated in British Columbia with its principal executive office in Vancouver, BC, operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing indicates routine corporate reporting by AbCellera Biologics Inc., providing updates on significant events and financial disclosures to the SEC.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate reporting and does not appear to contain any material non-public information that would immediately impact the stock price.
Key Numbers
- 001-39781 — SEC File Number (Identifies the company's filing with the SEC.)
Key Players & Entities
- AbCellera Biologics Inc. (company) — Registrant
- September 10, 2025 (date) — Date of Report
- Vancouver, BC (location) — Principal Executive Office
- 2834 (industry_code) — Standard Industrial Classification
FAQ
What is the primary purpose of this 8-K filing for AbCellera Biologics Inc.?
The filing serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on September 10, 2025.
Where is AbCellera Biologics Inc. headquartered?
The company's principal executive office is located at 150 W 4th Avenue, Vancouver, BC V5Y 1G6.
What is AbCellera Biologics Inc.'s Standard Industrial Classification code?
The SIC code for AbCellera Biologics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's state of incorporation?
AbCellera Biologics Inc. is incorporated in British Columbia.
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2025-09-10 12:23:15
Filing Documents
- abcl-20250910.htm (8-K) — 25KB
- pressrelease-cmo.htm (EX-99.1) — 4KB
- pressrelease-cmo001.jpg (GRAPHIC) — 153KB
- pressrelease-cmo002.jpg (GRAPHIC) — 81KB
- 0001703057-25-000018.txt ( ) — 461KB
- abcl-20250910.xsd (EX-101.SCH) — 2KB
- abcl-20250910_lab.xml (EX-101.LAB) — 20KB
- abcl-20250910_pre.xml (EX-101.PRE) — 12KB
- abcl-20250910_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On September 10, 2025, AbCellera Biologics Inc. (the "Company"), issued a press release announcing the appointment of Sarah Noonberg, M.D., Ph.D., as the Company's Chief Medical Officer. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release issued by AbCellera Biologics Inc. on September 10 , 2025. 104 Cover Page Interactive Data File (embedded as Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 10, 2025 ABCELLERA BIOLOGICS INC. By: /s/ Carl L. G. Hansen Carl L. G. Hansen, Ph.D. Chief Executive Officer and Director (Principal Executive Officer)